{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:55:46Z","timestamp":1773399346712,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Doctor Kasem Pangsrivongse Foundation, Thailand","award":["026\/2566"],"award-info":[{"award-number":["026\/2566"]}]},{"name":"Eastern Asia University, Thailand","award":["002\/2562"],"award-info":[{"award-number":["002\/2562"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: While non-vitamin K antagonist oral anticoagulants (NOACs) show better renal preservation than warfarin in nonvalvular atrial fibrillation (NVAF) patients, real-world evidence within Asian populations remains limited. This study compared the renal outcomes between NOACs and warfarin in Thai patients with NVAF. Materials and Methods: A retrospective cohort study was conducted among NVAF patients who received either NOACs or warfarin from two university hospitals in Thailand from January 2015 to December 2019. The primary outcome was a \u226530% decline in the estimated glomerular filtration rate (eGFR) with a doubling of the serum creatinine (SCr), while acute kidney injury (AKI) and incidence rate of stroke and systemic embolism event (SEE) were secondary outcomes. All outcomes of each NOAC versus the warfarin group were analyzed using Cox proportional hazards regression. Results: A total of 1456 patients were enrolled. During a follow-up period of 24 months, NOACs were associated with a lower risk of a \u226530% decline in the eGFR than warfarin after inverse probability of treatment weighting (IPTW) and multivariable adjustment (adjusted hazard ratio (aHR) of 0.67, 95% confidence interval [CI] 0.45\u20131.00, p = 0.050). No significant differences were observed between NOACs and warfarin regarding the doubling of SCr (aHR 0.64, 95% CI 0.24\u20131.72, p = 0.373) or AKI (aHR 0.69, 95% CI 0.41\u20131.17, p = 0.169), although a trend toward a lower risk was noted in the NOAC group. Similarly, a trend toward a lower risk of the incidence rate of ischemic stroke and SEE were observed in the NOAC group (aHR 0.49, 95% CI 0.22\u20131.10, p = 0.084). Conclusions: In real-world data, NOACs may be associated with a lower eGFR decline and lower doubling of SCr and AKI than warfarin. Additionally, NOACs may reduce the risk of ischemic stroke and SEE, supporting their potential benefit over warfarin in both renal and thromboembolic outcomes.<\/jats:p>","DOI":"10.3390\/medicina62030532","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:26:19Z","timestamp":1773390379000},"page":"532","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Renal Outcomes and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation: Insights from Real-World Data"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-7100","authenticated-orcid":false,"given":"Karatpetch","family":"Tongkate","sequence":"first","affiliation":[{"name":"The College of Pharmacotherapy of Thailand, Nonthaburi 11000, Thailand"},{"name":"Pharmaceutical Care Division, School of Pharmacy, Eastern Asia University, Pathum Thani 12110, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4192-1992","authenticated-orcid":false,"given":"Thoranis","family":"Chantrarat","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Phramongkutklao Hospital, Bangkok 10400, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-0924","authenticated-orcid":false,"given":"Pornwalai","family":"Boonmuang","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5839-440X","authenticated-orcid":false,"given":"Weerayuth","family":"Saelim","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-9619","authenticated-orcid":false,"given":"Narisa","family":"Ruenroengbun","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-1018","authenticated-orcid":false,"given":"Junporn","family":"Kongwatcharapong","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Faculty of Medicine Siriraj Hospital,   Mahidol University, Bangkok 10700, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Krittayaphong, R., Rangsin, R., Thinkhamrop, B., Hurst, C., Rattanamongkolgul, S., Sripaiboonkij, N., and Yindeengam, A. (2016). Prevalence and Associating Factors of Atrial Fibrillation in Patients with Hypertension: A Nation-Wide Study. BMC Cardiovasc. Disord., 16.","DOI":"10.1186\/s12872-016-0232-4"},{"key":"ref_2","first-page":"1147","article-title":"European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) Expert Consensus on Risk Assessment in Cardiac Arrhythmias: Use the Right Tool for the Right Outcome, in the Right Population","volume":"22","author":"Nielsen","year":"2020","journal-title":"EP Eur."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5334\/gh.1023","article-title":"World Heart Federation Roadmap on Atrial Fibrillation\u2013A 2020 Update","volume":"16","author":"Freedman","year":"2021","journal-title":"Glob. Heart"},{"key":"ref_4","first-page":"100709","article-title":"Atrial Fibrillation Prevalence and Risk Profile from Novel Community-Based Screening in Thailand: A Prospective Multi-Centre Study","volume":"32","author":"Suwanwela","year":"2021","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"04154","DOI":"10.7189\/jogh.13.04154","article-title":"Global, Regional, and National Burdens of Atrial Fibrillation\/Flutter from 1990 to 2019: An Age-Period-Cohort Analysis Using the Global Burden of Disease 2019 Study","volume":"13","author":"Li","year":"2023","journal-title":"J. Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/STROKEAHA.112.676551","article-title":"Atrial Fibrillation in Ischemic Stroke: Predicting Response to Thrombolysis and Clinical Outcomes","volume":"44","author":"Saposnik","year":"2013","journal-title":"Stroke"},{"key":"ref_8","first-page":"937","article-title":"The Impact of Ischaemic Stroke on Atrial Fibrillation-Related Healthcare Cost: A Systematic Review","volume":"19","author":"Li","year":"2017","journal-title":"Europace"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2478\/abm-2025-0028","article-title":"2025 Thai Guideline for the Diagnosis and Management of Atrial Fibrillation","volume":"19","author":"Ngarmukos","year":"2025","journal-title":"Asian Biomed. (Res. Rev. News)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"c142","DOI":"10.1159\/000312877","article-title":"Warfarin Therapy That Results in an International Normalization Ratio above the Therapeutic Range Is Associated with Accelerated Progression of Chronic Kidney Disease","volume":"115","author":"Brodsky","year":"2010","journal-title":"Nephron Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"An, J.N., Ahn, S.Y., Yoon, C.-H., Youn, T.-J., Han, M.-K., Kim, S., Chin, H.J., Na, K.Y., and Chae, D.-W. (2013). The Occurrence of Warfarin-Related Nephropathy and Effects on Renal and Patient Outcomes in Korean Patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057661"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.krcp.2014.11.001","article-title":"Anticoagulants and Acute Kidney Injury: Clinical and Pathology Considerations","volume":"33","author":"Brodsky","year":"2014","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bcpt.12834","article-title":"Vascular Calcification, Vitamin K and Warfarin Therapy-Possible or Plausible Connection?","volume":"122","author":"Siltari","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic Effects of Factor Xa and Thrombin: What to Expect from Novel Anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.3390\/nu7115479","article-title":"New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)","volume":"7","author":"Schurgers","year":"2015","journal-title":"Nutrients"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal Outcomes in Anticoagulated Patients with Atrial Fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e008150","DOI":"10.1161\/JAHA.117.008150","article-title":"Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians with Nonvalvular Atrial Fibrillation","volume":"7","author":"Chan","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1076029619868535","DOI":"10.1177\/1076029619868535","article-title":"Rivaroxaban\u2019s Impact on Renal Decline in Patients with Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis","volume":"25","author":"Coleman","year":"2019","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jjcc.2019.06.003","article-title":"Real-World Outcomes of Rivaroxaban Treatment in Patients with Nonvalvular Atrial Fibrillation and Worsening Renal Function","volume":"74","author":"Nakagawara","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ehjqcco\/qcz047","article-title":"Rivaroxaban vs. Warfarin and Renal Outcomes in Non-Valvular Atrial Fibrillation Patients with Diabetes","volume":"6","author":"Hernandez","year":"2020","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_26","first-page":"100844","article-title":"The Change of Renal Functions after Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"35","author":"Chantrarat","year":"2021","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012). Section 2: AKI Definition. Kidney Int. Suppl., 2, 19\u201336.","DOI":"10.1038\/kisup.2011.32"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.ajkd.2022.07.017","article-title":"Cardiorenal Outcomes Among Patients with Atrial Fibrillation Treated with Oral Anticoagulants","volume":"81","author":"Trevisan","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","first-page":"24","article-title":"Renal Outcomes in Asian Patients Receiving Oral Anticoagulants for Non-Valvular Atrial Fibrillation","volume":"28","author":"Shahzada","year":"2022","journal-title":"Hong Kong Med. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00467-008-0789-y","article-title":"Therapeutic Strategies to Slow Chronic Kidney Disease Progression","volume":"23","author":"Schaefer","year":"2008","journal-title":"Pediatr. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.23876\/j.krcp.2018.37.2.103","article-title":"Atrial Fibrillation and Chronic Kidney Disease: A Bad Combination","volume":"37","author":"Kiuchi","year":"2018","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000502105","article-title":"New Approach to Slowing the Progression of Chronic Kidney Disease","volume":"9","author":"Solomon","year":"2019","journal-title":"Cardiorenal Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijcard.2022.01.063","article-title":"Renal Decline in Patients with Non-Valvular Atrial Fibrillation Treated with Rivaroxaban or Warfarin: A Population-Based Study from the United Kingdom","volume":"352","author":"Balabanova","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/jpet.112.194837","article-title":"The Effects of Direct Thrombin Inhibition with Dabigatran on Plaque Formation and Endothelial Function in Apolipoprotein E-Deficient Mice","volume":"343","author":"Lee","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.jacc.2016.08.063","article-title":"Acute Kidney Injury in Asians with Atrial Fibrillation Treated with Dabigatran or Warfarin","volume":"68","author":"Chan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/cpt.2090","article-title":"Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country","volume":"109","author":"Mitsuntisuk","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding","volume":"127","author":"Eriksson","year":"2013","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cumitini, L., Renda, G., Giordano, M., Rolla, R., Shail, T., Sacchetti, S., Iezzi, L., Giacomini, L., Zanotti, V., and Auciello, R. (2024). Role of CES1 and ABCB1 Genetic Polymorphisms on Functional Response to Dabigatran in Patients with Atrial Fibrillation. J. Clin. Med., 13.","DOI":"10.2139\/ssrn.4727945"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Raymond, J., Imbert, L., Cousin, T., Duflot, T., Varin, R., Wils, J., and Lamoureux, F. (2021). Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J. Pers. Med., 11.","DOI":"10.3390\/jpm11010037"},{"key":"ref_41","first-page":"e007956","article-title":"Drug Interactions Affecting Oral Anticoagulant Use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ. Arrhythmia Electrophysiol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/532\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:08:45Z","timestamp":1773392925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicina62030532"],"URL":"https:\/\/doi.org\/10.3390\/medicina62030532","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}